ECSP099078A - Derivados de amino-piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp) - Google Patents

Derivados de amino-piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)

Info

Publication number
ECSP099078A
ECSP099078A EC2009009078A ECSP099078A ECSP099078A EC SP099078 A ECSP099078 A EC SP099078A EC 2009009078 A EC2009009078 A EC 2009009078A EC SP099078 A ECSP099078 A EC SP099078A EC SP099078 A ECSP099078 A EC SP099078A
Authority
EC
Ecuador
Prior art keywords
transfer protein
ester transfer
cetp
cholesteril
inhibitors
Prior art date
Application number
EC2009009078A
Other languages
English (en)
Inventor
Takahiro Miyake
Osamu Ohmori
Ichiro Umemura
Muneto Mogi
Yuki Iwaki
Hidetomo Imase
Toshio Kawanami
Hongbo Qin
Ken Yamada
Kayo Yasoshima
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38695303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP099078(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP099078A publication Critical patent/ECSP099078A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un compuesto de la fórmula (I); en donde las variantes R1, R2, R3, R4, R5, R6, R7 son como se definen en la presente, y en donde este compuesto es un inhibidor de la proteína de transferencia de colesteril-éster (CETP), y por lo tanto, se puede emplear para el tratamiento de un trastorno o enfermedad mediada por la proteína de transferencia de colesteril-éster o que responda a la inhibición de la proteína de transferencia de colesteril-éster.
EC2009009078A 2006-07-20 2009-01-19 Derivados de amino-piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp) ECSP099078A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06117541 2006-07-20
US88705807P 2007-01-29 2007-01-29

Publications (1)

Publication Number Publication Date
ECSP099078A true ECSP099078A (es) 2009-02-27

Family

ID=38695303

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009078A ECSP099078A (es) 2006-07-20 2009-01-19 Derivados de amino-piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)

Country Status (22)

Country Link
US (1) US20090286790A1 (es)
EP (1) EP2049517B1 (es)
JP (1) JP5042311B2 (es)
KR (1) KR101149274B1 (es)
AR (1) AR061926A1 (es)
AU (1) AU2007276433B2 (es)
CA (1) CA2657258A1 (es)
CL (1) CL2007002107A1 (es)
CO (1) CO6150155A2 (es)
CR (1) CR10478A (es)
EC (1) ECSP099078A (es)
GT (1) GT200900010A (es)
HR (1) HRP20140183T1 (es)
IL (1) IL195792A (es)
MA (1) MA30638B1 (es)
MX (1) MX2009000646A (es)
NO (1) NO342106B1 (es)
PE (1) PE20080404A1 (es)
PL (1) PL2049517T3 (es)
TN (1) TN2009000012A1 (es)
TW (1) TWI387593B (es)
WO (1) WO2008009435A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010533147A (ja) * 2007-07-13 2010-10-21 アデックス ファルマ エス.エイ. 代謝調節型グルタミン酸レセプターのモジュレーターとしてのピラゾール誘導体
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
SI2207775T1 (sl) 2007-11-05 2012-05-31 Novartis Ag benzilamino karboksiacil piperidinski derivati kot inhibitorji CETP uporabni za zdravljenje bolezni kot je hiperlipidemija ali arterioskleroza
CN101878199B (zh) * 2007-12-03 2013-09-18 诺瓦提斯公司 用于治疗例如高血脂或动脉硬化疾病的作为cetp抑制剂的1,2-二取代的-4-苄基氨基-吡咯烷衍生物
US8258306B2 (en) 2007-12-12 2012-09-04 Amgen Inc. Glycine transporter-1 inhibitors
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2592076B1 (en) 2010-07-09 2015-05-13 Daiichi Sankyo Company, Limited Substituted pyridine compound
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
PL2729142T3 (pl) * 2011-07-08 2018-10-31 Novartis Ag Sposób leczenia miażdżycy tętnic u osobników z wysokim poziomem triglicerydów
US9321747B2 (en) 2012-01-06 2016-04-26 Daiichi Sankyo Company, Limited Acid addition salt of substituted pyridine compound
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
JP6295277B2 (ja) 2013-02-14 2018-03-14 ノバルティス アーゲー Nep(中性エンドペプチダーゼ)阻害剤としての置換ビスフェニルブタン酸ホスホン酸誘導体
JP2014172851A (ja) * 2013-03-07 2014-09-22 Chiba Univ ピラゾール誘導体の製造方法およびイソオキサゾール誘導体の製造方法
TW201536814A (zh) 2013-07-25 2015-10-01 Novartis Ag 用於治療心臟衰竭之合成環狀多肽
PE20160991A1 (es) 2013-07-25 2016-10-15 Novartis Ag Bioconjugados de polipeptidos de apelina sintetica
JP6402907B2 (ja) * 2014-09-24 2018-10-10 Jnc株式会社 ピペリジン誘導体、液晶組成物および液晶表示素子
WO2016116842A1 (en) 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
MX2022001940A (es) 2019-08-14 2022-05-10 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
CN110508018B (zh) * 2019-09-03 2022-02-25 中国石油大学(华东) 生产聚甲氧基二甲醚的装置及方法
CN119930610A (zh) 2019-10-11 2025-05-06 因赛特公司 作为cdk2抑制剂的双环胺
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
TW313568B (es) 1994-12-20 1997-08-21 Hoffmann La Roche
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
CA2345103C (en) 1998-09-25 2011-04-26 Monsanto Company (r)-chiral halogenated 1-substitutedamino-(n+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity
KR101476067B1 (ko) 2002-09-06 2014-12-23 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
KR20060114376A (ko) 2004-01-30 2006-11-06 니뽄 다바코 산교 가부시키가이샤 식욕 감퇴 화합물
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
CN101878199B (zh) * 2007-12-03 2013-09-18 诺瓦提斯公司 用于治疗例如高血脂或动脉硬化疾病的作为cetp抑制剂的1,2-二取代的-4-苄基氨基-吡咯烷衍生物

Also Published As

Publication number Publication date
CA2657258A1 (en) 2008-01-24
KR20090031579A (ko) 2009-03-26
EP2049517A1 (en) 2009-04-22
WO2008009435A1 (en) 2008-01-24
TN2009000012A1 (en) 2010-08-19
MX2009000646A (es) 2009-01-29
CL2007002107A1 (es) 2008-06-06
TW200813022A (en) 2008-03-16
CR10478A (es) 2009-02-02
JP2009543827A (ja) 2009-12-10
IL195792A (en) 2013-07-31
NO342106B1 (no) 2018-03-26
HRP20140183T1 (hr) 2014-04-11
PE20080404A1 (es) 2008-06-27
AU2007276433B2 (en) 2011-06-16
NO20090756L (no) 2009-04-14
MA30638B1 (fr) 2009-08-03
HK1132262A1 (en) 2010-02-19
KR101149274B1 (ko) 2012-05-29
IL195792A0 (en) 2009-09-01
CO6150155A2 (es) 2010-04-20
AR061926A1 (es) 2008-10-01
GT200900010A (es) 2009-06-24
AU2007276433A1 (en) 2008-01-24
JP5042311B2 (ja) 2012-10-03
EP2049517B1 (en) 2013-11-27
PL2049517T3 (pl) 2014-06-30
TWI387593B (zh) 2013-03-01
US20090286790A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
ECSP099078A (es) Derivados de amino-piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
EA201000884A1 (ru) Производные 1,2-дизамещенного 4-бензиламинопирролидина в качестве ингибиторов белка-переносчика холестерилового эфира, используемые для лечения заболеваний, таких как гиперлипидемия или артериосклероз
CY1112706T1 (el) Παραγωγα 4-βενζυλαμινο-1-καρβοξυακυλ-πιπεριδινης ως αναστολεις της cετρ, χρησιμοι για τη θεραπεια ασθενειων οπως η υπερλιπιδαιμια ή η αρτήριοσκληρωση
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
NI201000107A (es) Derivados de tiazol utilizados como inhibidores de pi 3 - cinasa.
NI201100166A (es) Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa
CR20110440A (es) Compuestos de piridazinona
UY32730A (es) Inhibidores de cyp17
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
EA201100447A1 (ru) Органические соединения
GT201100181A (es) "inhibidores de proteina cinasa"
BR112014009993A2 (pt) método para o tratamento de tumores do estroma gastrointestinal
CU20120071A7 (es) DERIVADOS DE N1-PIRAZOLOESPIROCETONA ÚTILES COMO INHIBIDORES DE ACETIL-CoA CARBOXILASA
BR112012008147A2 (pt) compostos heteroarílicos como inibidores da quinase
ECSP088891A (es) Derivados bicíclicos como inhibidores de cetp
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
PA8640701A1 (es) Indazoles utiles para tratamiento de enfermedades cardiovascular
CR10868A (es) Derivados de dihidropiridina utiles como inhibidores de la proteina quinasa
UY32123A (es) Derivados de n - (sustituido) - 4 - (but-2-iniloxi) - benzamida, sus racematos, diastereòmeros, enantiòmeros y las sales de los mismos y aplicaciones
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
EA201170832A1 (ru) Пуриновые соединения
HN2010000313A (es) Pirimidinas biciclicas fusionadas
BR112018069147A2 (pt) composto da fórmula iii, composição farmacêutica, método de inibição da função de fimh e método de tratamento de uma doença mediada por fimh
BRPI0720050A2 (pt) 6-oxo-1,6-diidropirimidin-2-ilas no tratamento de doenças proliferativas
EA201170828A1 (ru) Конденсированные гетероциклические производные оксадиазола, подходящие для лечения рассеянного склероза